Applied Therapeutics, Inc. (APLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
APLT Stock Price Chart Interactive Chart >
APLT Price/Volume Stats
| Current price | $0.87 | 52-week high | $10.77 |
| Prev. close | $0.84 | 52-week low | $0.50 |
| Day low | $0.80 | Volume | 176,300 |
| Day high | $0.89 | Avg. volume | 374,998 |
| 50-day MA | $0.79 | Dividend yield | N/A |
| 200-day MA | $1.33 | Market Cap | 41.81M |
Applied Therapeutics, Inc. (APLT) Company Bio
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY
Latest APLT News From Around the Web
Below are the latest news stories about APPLIED THERAPEUTICS INC that investors may wish to consider to help them evaluate APLT as an investment opportunity.
Applied Therapeutics Reports Third Quarter 2022 Financial ResultsNEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In the third quarter, we made significant progress across all three of our late-stage programs,” said Shoshana Shendelman, PhD, Founder, CEO and C |
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodelingBaseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as an important metric of quality of life and physical functioning in Diabetic Cardiomyopathy patients NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical |
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic CardiomyopathyARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placeboPrimary study endpoint is cardiac functional capacity (measured by Peak VO2) at 15 monthsDbCM is a form of heart failure affecting approximately 20% of Type 2 Diabetes patients (~6M patients in the US and ~5M in EU), which represents a significant commercial market opportunityThere are currently no treatme |
Insiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62The recent price decline of 33% in Applied Therapeutics, Inc.'s ( NASDAQ:APLT ) stock may have disappointed insiders... |
Applied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical SignificanceApplied Therapeutics Inc's (NASDAQ: APLT) ACTION-Galactosemia Kids Phase 3 trial has demonstrated a trend in clinical benefit favoring AT-007 vs. placebo. The study is designed to evaluate the impact of AT-007 vs. placebo on clinical outcomes in children with Classic Galactosemia, with a review of safety and efficacy every six months. Classic galactosemia is an inherited condition in which the body cannot properly digest galactose, a sugar found in all foods containing milk. The sugar buildup ca |
APLT Price Returns
| 1-mo | 33.89% |
| 3-mo | -40.41% |
| 6-mo | -37.86% |
| 1-year | -91.10% |
| 3-year | -95.85% |
| 5-year | N/A |
| YTD | -90.28% |
| 2021 | -59.34% |
| 2020 | -19.32% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...